top of page

Pharmaceutical Overview

Nutra Pharma is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases in humans. The emphasis of Nutra Pharma's approach to drug discovery and the development of new therapeutic agents is based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from cobras.

Leading Drug Candidates


RPI-MN inhibits the entry of several viruses that are known to cause severe neurological damage in such diseases as encephalitis and AIDS. It is being developed first for the treatment of HIV. and Herpes.


RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological and autoimmune disorders that may be served by RPI-78M include myasthenia gravis (MG), rheumatoid arthritis (RA)  and amyotrophic lateral sclerosis (ALS).

*RPI-78M has received Orphan Drug Designation from the FDA for the  treatment of Pediatric Multiple Sclerosis

RPI-78M and RPI-MN contain anticholinergic peptides that recognize the same receptors as nicotine (acetylcholine receptors) but have the opposite effect. In a specific chemical process unique to Nutra Pharma, the drugs are created through a process of chemical modification and possess several desirable properties as drugs, including: 

  • They lack measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose. 

  • They display no serious adverse side effects following years of investigations in humans and animals. 

  • They are extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs' stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug. 

  • They are easy to administer. 

  • RPI-78M can be administered orally-a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.



Nutra Pharma is taking on some of the world's most difficult diseases including:

RPI-MN: Modified Cobra Venom for Viral Diseases


Herpes is a group of related diseases marked by the development of blisterlike sores on the skin or mucous membranes of the body.

Human Immunodeficiency Virus (HIV / AIDS)

The Human Immunodeficiency Virus (HIV) is the virus that causes AIDS, a debilitating and deadly disease of the human immune system. The World Health Organization (WHO) estimates that 35 million people have died from AIDS since 1981. It is estimated that at the end of 2016, there were more than 36 million people worldwide living with HIV.

RPI-78M: Modified Alpha Cobratoxin for Autoimmune Diseases

Adrenomyeloneuropathy (AMN)

Adrenomyeloneuropathy (AMN) is a rare inherited metabolic disorder that effects approximately 20,000 people globally. Its symptoms are very similar to those of progressive Multiple Sclerosis (MS). 

Multiple Sclerosis (MS) 

Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system causing muscular weakness, loss of coordination, and speech and visual disturbances. There are approximately 2,000,000 people living with MS worldwide.

bottom of page